Stay informed about the FTC’s proposed settlement with Express Scripts (as of February 2026) and the pricing, formulary, and reporting changes that could materially influence your pharmacy strategy in the near future.
In this 12-minute video explainer, Truveris Clinical Director Sarah Berry, PharmD, breaks down the FTC proposed settlement with Express Scripts, including what’s changing, what may follow at other PBMs, and what plan sponsors should do next.
Video Highlights
- Based on the Express Scripts settlement terms, learn how formulary rules, point‑of‑sale rebates, and net‑price cost‑share could impact member affordability and plan budgets.
- Understand how PBM compensation decoupling and emerging fee models may change guarantees, rebate constructs, and contract governance, starting with ESI.
- See why expanded drug‑level reporting and GPO reshoring raise the bar for definitions, auditability, and flow‑of‑funds transparency.
- Prepare for DTC channels (e.g., TrumpRx) to count toward ESI deductibles and accumulators, and what that could mean for Express Scripts pharmacy contracts and member communications.
- Anticipate shifts to retail reimbursement (e.g., cost‑plus) and re‑evaluate narrow vs. open networks to balance access and savings.
Watch: FTC and ESI Explainer Video
